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AbstrACt
Objectives More than 80% of cardiovascular diseases 
(CVD) and diabetes mellitus (DM) burden now lies in low 
and middle-income countries. Hence, there is an urgent 
need to identify and implement the most cost-effective 
interventions, particularly in the resource-constraint South 
Asian settings. Thus, we aimed to systematically review 
the cost-effectiveness of individual-level, group-level and 
population-level interventions to control CVD and DM in 
South Asia.
Methods We searched 14 electronic databases up to 
August 2016. The search strategy consisted of terms 
related to ‘economic evaluation’, ‘CVD’, ‘DM’ and ‘South 
Asia’. Per protocol two reviewers assessed the eligibility 
and methodological quality of studies using standard 
checklists, and extracted incremental cost-effectiveness 
ratios of interventions.
results Of the 2949 identified studies, 42 met full 
inclusion criteria. Critical appraisal of studies revealed 
15 excellent, 18 good and 9 poor quality studies. Most 
studies were from India (n=37), followed by Bangladesh 
(n=3), Pakistan (n=2) and Bhutan (n=1). The economic 
evaluations were based on observational studies (n=9), 
randomised trials (n=12) and decision models (n=21). 
Together, these studies evaluated 301 policy or clinical 
interventions or combination of both. We found a large 
number of interventions were cost-effective aimed at 
primordial prevention (tobacco taxation, salt reduction 
legislation, food labelling and food advertising regulation), 
and primary and secondary prevention (multidrug 
therapy for CVD in high-risk group, lifestyle modification 
and metformin treatment for diabetes prevention, and 
screening for diabetes complications every 2–5 years). 
Significant heterogeneity in analytical framework and 
outcome measures used in these studies restricted meta-
analysis and direct ranking of the interventions by their 
degree of cost-effectiveness.
Conclusions The cost-effectiveness evidence for CVD 
and DM interventions in South Asia is growing, but most 
evidence is from India and limited to decision modelled 
outcomes. There is an urgent need for formal health 
technology assessment and policy evaluations in South 
Asia using local research data.
PrOsPErO registration number CRD42013006479.
IntrOduCtIOn 
Evidence from randomised trials suggests that 
both pharmacological and non-pharmaco-
logical strategies are important in prevention 
and management of cardiovascular diseases 
(CVD) and diabetes mellitus (DM).1–12 While 
there is strong evidence on cost-effectiveness 
of pharmaceutical and lifestyle interventions 
in reducing the CVD and DM risk in affluent 
settings,13–16 little is known about the compar-
ative cost-effectiveness of various interven-
tions to control CVD and DM in South Asia. 
To generalise results from high-income 
countries to low and middle-income coun-
tries (LMICs) is not entirely justified because 
reasonable thresholds for cost-effectiveness 
will vary markedly—as will affordability. Also, 
setting specific cost-effectiveness information 
strengths and limitations of this study
 ► This is the first systematic review to synthesise 
cost-effectiveness evidence on all types of inter-
ventions (policy, clinical or behavioural) to control 
cardiovascular diseases and diabetes mellitus in 
South Asia.
 ► This review used a rigorous and broad search strat-
egy including a wide range of sources to ensure all 
published studies are included for review.
 ► This review used explicitly stated methods (protocol 
paper published) and standard checklists to assess 
methodological quality of studies.
 ► The search was confined to English language pub-
lications performed as of August 2016, and this 
review excluded unpublished and ‘grey’ literature 
domain as we wanted to include studies that have 
undergone peer review process.
 ► Significant heterogeneity in analytical framework 
and outcome measures used in these studies re-
stricted meta-analysis and direct ranking of the 
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is important because of the differences in healthcare 
infrastructure.
With the rapidly increasing prevalence of CVD and 
DM in South Asia and the consequent huge economic 
losses, coupled with ill-equipped health systems and 
scarce resources to tackle the burden of chronic condi-
tions, it is imperative to promote the most cost-effective 
interventions in this region. While a large number of 
economic evaluations have been recently performed 
in context to LMICs, and some authors have reviewed 
the available literature on non-communicable diseases 
broadly,17 18 no systematic attempt has been made so far 
to compile the evidence base and appraise the method-
ological quality of the economic evaluations of interven-
tions to control CVD and DM in South Asia. To the best 
of our knowledge, no review has considered the cost-ef-
fectiveness evidence of interventions to control CVD 
and DM simultaneously, although these diseases share 
common risk factors.
We systematically reviewed the cost-effectiveness 
evidence on individual-level, group-level and popula-
tion-level interventions to control CVD and DM in South 
Asia. The specific objectives were the following:
1. to summarise the incremental resource use, costs, 
consequences and cost-effectiveness of interventions 
versus comparators to control CVD and DM in South 
Asia
2. to describe the quality of economic evaluations con-
sidering key methodological issues.
research design and methods
A protocol for the systematic review has been published 
previously and it provides a detailed description of the 
methodology, used for the current study.19 The system-
atic review has been registered previously in PROSPERO 
(CRD42013006479).
Briefly, we searched for studies that met the following 
inclusion criteria:
1. type of studies: full economic evaluations (cost-ef-
fectiveness analysis, cost-utility analysis, cost-benefit 
analysis) based on randomised trials or observational 
studies or decision models
2. type of participants: studies that included individu-
als with either established DM or CVD or at risk of 
developing these diseases in one of the South Asian 
countries: Afghanistan, Bangladesh, Bhutan, India, 
Pakistan, Maldives, Nepal and Sri Lanka
3. types of interventions: interventions or strategies for 
prevention and treatment of CVD or DM as docu-
mented in the previously published protocol19
4. types of outcome measures: we included several out-
comes broadly under three domains—resource use, 
costs and cost-effectiveness as incremental cost per 
quality-adjusted life years (QALYs) gained, or disabil-
ity-adjusted life years (DALYs) averted, or life years 
gained or intermediate outcomes; a detailed list has 
been presented in the previously published protocol19
5. studies published in the English language.
We searched 14 electronic databases and hand-searched 
for publications of the Disease Control Priorities Project 2 
(DCPP2) and the WHO-Choosing Interventions that are 
Cost-Effective (WHO-CHOICE) to identify relevant studies. 
The details of the databases searched and a search strategy 
are provided in supplementary web appendix 1.
Critical appraisal of included studies
Checklists proposed by Drummond et al,20 Evers et al21 and 
Philips et al22 were used for data extraction and to review 
methodological quality and strength of economic evidence. 
Also, we looked for funding sources of included studies.
Analysing, interpreting and reporting results
We extracted the incremental cost, incremental effect 
and incremental cost-effectiveness ratios (ICER) for 
interventions evaluated in the eligible studies. To adjust 
for cost and varying currencies over time, we used coun-
try-specific consumer price inflation rate to present value 
in 2017 and then used midyear currency conversion.23 24 
All costs were converted to US$ (2017). Data extraction 
and critical appraisal of included studies were conducted 
by two authors independently and differences if any were 
resolved by consensus.
We used country-specific gross domestic product 
(GDP) per capita threshold, as per WHO guidelines,25 
to interpret the ICER for all interventions evaluated 
in this review. We colour-coded ICER estimates as per 
the following scheme:
 ► green=ICER<1×GDP per capita per QALY gained 
(highly cost-effective)
 ► yellow=1–3×GDP per capita per QALY gained 
(cost-effective)
 ► red=ICER>3×GDP per capita per QALY gained (not 
cost-effective).
Interventions that resulted in a negative incremental 
effect were regarded as dominated strategy and no ICER 
was reported. Further, we synthesised the cost-effective-
ness data and presented the ICER for policy or clinical 
interventions, separately in the following categories: 
primordial, primary, secondary and tertiary prevention.
difference between protocol and full review
We have not planned to include economic evaluations 
based on observational studies in the protocol but we 
have included it in our review. The more inclusive criteria 
enabled us to provide a more comprehensive review of 
the evidence base surrounding the topic. Risk of bias 
assessment in randomised trials was not conducted using 
Cochrane methods as Drummond and Evers checklists 
are inclusive of methodological quality assessments of 
economic evaluations alongside randomised trials as well.
rEsults
search results
Our first search yielded 2949 items, titles and abstracts 
screening resulted in 85 articles, and full-text screening 
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Characteristics of included studies
Table 1 shows the detailed description of the studies 
(n=42) by country/setting, study population, interven-
tion(s), comparator(s), economic perspective and type of 
analysis, and outcome measures.
Study design
The economic evaluations were based on observational 
studies (n=9), randomised controlled trials (RCT) (n=12) 
and decision models (n=21).
Study setting
Most studies were from India (n=37), followed by Bangla-
desh (n=3), Pakistan (n=2) and Bhutan (n=1). Decision 
modelling studies had used effectiveness data mostly 
from meta-analysis of RCTs that reported results from 
developed countries.
Study population
Individuals (or population) at risk or with established 
CVD or DM were included.
Intervention targets and comparators
Three hundred and one interventions (policy, clinical 
or behavioural) were evaluated against null scenario (no 
intervention) or active comparators.
Perspective
In two-thirds of the studies (n=28), the authors explicitly 
documented and justified the economic perspective of 
the study. The studies used ‘health system’,  that is, direct 
Figure 1 PRISMA flow chart for the selection of economic evaluations of interventions to control cardiovascular disease and 
diabetes mellitus in South Asia. CEA, cost-effectiveness analysis; CINAHL, Cumulative Index to Nursing and Allied Health 
Literature; CRD, Centre for Reviews and Dissemination; CVD, cardiovascular disease; DCPP2, Disease Control Priorities Project 
2; EE, economic evaluation; HEED, Health Economic Evaluation Database; PRISMA, Preferred Reporting Items for Systematic 
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costs incurred by the health system (n=26); ‘patient’, that 
is, out-of-pocket payments by patient (n=6); or ‘societal’, 
that is, inclusive of all direct and indirect costs, plus 
productive loss (n=6) perspectives. Five studies did not 
state any perspective.
Funding
Two-thirds of evaluations (n=29) provided statements 
on the funding source. Public sponsorship or chari-
table trust/foundation grant was most common (n=16), 
followed by pharmaceutical industry (n=6) or received no 
support (n=7). A large number of studies did not state 
their source of research funding (n=13).
Resource use and costs
Only 20% of the studies (n=8) reported types and quan-
tities of resource use and unit costs separately. Of these, 
five were RCT-based economic evaluations and two were 
decision model studies, suggesting that RCT provides an 
advantage on the reporting of actual resource use data as 
it is being collected during the trial.
Mostly direct medical costs were considered, although 
the scope of this varied enormously. For instance, 14 
studies included only cost of intervention (medicines, 
diagnostics), while others (n=28) included cost of 
training, delivery of intervention, associated healthcare 
visit costs and travel cost of patients to the healthcare 
facility. Most (n=27) appeared to use an ‘ingredients’ 
costing approach, where costs were broken down between 
the main cost components such as medications, health-
care visits, vehicles, salaries and consumables. Fewer 
(n=5) used an ‘activity’-based approach, by identifying 
specific tasks such as programme and therapy costs. Two 
studies appeared to use some combination of the two, 
and it was not possible to discern the approach for eight 
papers. Few studies (n=6) also included ‘productivity 
losses’ (often termed ‘indirect costs’) in their assessment 
of costs, which were measured using the ‘human capital 
approach’.
Regardless of the approach taken, most papers (n=21) 
presented aggregated cost information. Many studies 
used actual expenditure data (n=17) as their source 
of costs data. Seven studies used published sources to 
generate cost estimates sometimes supplemented with 
expert opinion. Currencies reported were mostly in US$ 
(n=25), international dollars (n=4) or local currencies 
(Indian rupees/Bhutanese rupees) (n=6). In addition, 
seven studies quoted costs in both US$ and the local 
currency.
Outcome measures (consequences)
Nearly half of the studies (n=21) used ‘life years gained’ 
or ‘QALYs’ or ‘DALYs’ in their analysis. The calculation of 
QALYs/DALYs was based on South Asian population life 
expectancies; however, the utility values (QALYs weight) 
were derived from developed countries. Disability weights 
used in the WHO-CHOICE-based decision model studies 
were derived from the Global Burden of Disease (GBD) 
study (2000).26 The remaining studies reported interme-
diate outcome measures such as number needed to treat, 
length of hospital stay, hospitalisation rate, blood pres-
sure (BP) reduction or CVD events avoided, which are 
easier to measure but harder to compare across interven-
tions. None of the studies expressed outcomes (benefits) 
in monetary units.
Time horizon
Three-fourths of studies (n=31) explicitly stated their 
analytical time horizon. Eighty per cent of decision model 
studies adopted lifetime horizon and others reported 
cost-effectiveness estimates for 10, 20, 25, 30 or 50 years. 
RCT/observational studies-based economic evaluations 
had a median time horizon of 1 year.
Discounting
A discount rate of 3% was most often used for both 
costs and effects in decision model studies. RCT-based 
economic evaluations used a discount rate of 3% (n=3) 
and 5% (n=1). Further, 11 studies did not apply any 
discount rate.
Analytical approach
Cost-effectiveness analysis or cost-utility analysis were the 
main methods (n=34), followed by cost-consequences 
analysis (n=6) and cost-minimisation analysis (n=2). 
Although several of these papers (n=8) described them-
selves as cost-effectiveness analysis, they were in fact 
cost-consequences analysis or cost-minimisation analysis 
because an incremental analysis was not reported or 
there was no significant difference in the effectiveness 
of the intervention versus comparator, respectively. Most 
studies reported average cost-effectiveness ratio and inter-
preted it as ICER against the comparator as null scenario, 
that is, no intervention.
We found several different types of decision models 
used for cost-effectiveness analysis. A large majority of 
the studies used the WHO-CHOICE state transition 
model. Others used coronary heart disease (CHD) policy 
model, GeDiForCE, IMS Centre for Outcomes Research 
Diabetes Model, Centers for Disease Control and Preven-
tion (CDC) model, Markov model or individual micro-
simulation model. Few studies provided details of model 
validation.
Sensitivity analyses and generalisability of study results
Nearly half of the studies (n=25) undertook some form 
of sensitivity analysis to assess the robustness of their find-
ings to assumptions about input parameters. Of these, 
one-way sensitivity analysis was most often applied. Two 
studies used threshold analysis and one performed a 
multi-way sensitivity analysis. None considered the struc-
tural variations in the decision model for sensitivity anal-
ysis. Few studies described the model validation methods.
Three-quarters of the studies (n=32) discussed the 
generalisability issue. Efforts were largely confined to 
stating the limitations of the study, such as whether 
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about the study site which might limit generalisability to 
other contexts. Another 12 studies discussed issues of 
affordability but in brief terms, for example, by noting 
that the available budget should be taken into account 
(most studies focused on the cost-effectiveness without 
considering the budget impact/constraint) or by ques-
tioning the sustainability of a novel service such as a 
mobile diabetic retinopathy services, where there are 
already existing health services.27
risk of bias assessment
In our critical review of methods used in economic eval-
uations to assess risk of bias, we found that almost all 
economic evaluations based on observational study only 
presented costs and consequences of two treatment strat-
egies separately, without reporting an ICER or employed 
sensitivity analysis to assess robustness of costs or treat-
ment effect estimates. Also, estimates of treatment effects 
from the observational studies are not very reliable due to 
the limitations in the original study design. On the other 
hand, economic evaluations based on RCTs reported 
better economic outcomes, that is, ICERs; however, 
these studies were limited by short follow-up duration 
(30 days to 1 or 2 years), treatment effects assessed as 
intermediate clinical outcomes (BP reduction, number 
needed to prevent one DM case) and mostly direct 
medical costs from health system perspective or patient 
perspective were reported, which ignores the societal 
costs and productivity loss due to illness. Lastly, decision 
modelling studies reported ICER per QALY gained or 
DALY averted mostly using the WHO-CHOICE methods, 
Markov models or microsimulation models from soci-
etal or health system perspectives. Many of the decision 
model studies from DCPP did not report the source of 
costs data, source of QALY weights and details on deci-
sion model structure or validation methods. Further, 
most of the WHO-CHOICE-based generalised cost-effec-
tiveness analysis used disability weights from an earlier 
version of the GBD study (2000). Therefore, findings 
from this review should be used with caution for local 
decision making, and there is an urgent need for more 
investment in local research to generate evidence/data 
on costs of treatment and health services and effective-
ness of interventions (table 1).
Methodological quality: summary
Figures 2 and 3 report the overall quality of studies 
based on the key methodological issues and technical 
characteristics for decision model studies, respec-
tively. In general, very few studies reported quantities 
of resource use data and unit costs separately, details 
of statistical tests used and CI around ICER estimates. 
Among decision model studies, none reported methods 
used to assess methodological, structural or heteroge-
neity uncertainties, and very few discussed model valida-
tion methods. Critical appraisal of studies revealed that 
there were 15 excellent (++), 18 good (+) and 9 poor 
quality studies (−) (table 2).
Figure 2 Methodological quality of included studies. This figure presents the number of studies meeting the key 
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Cost-effectiveness evidence
Interventions reviewed for their cost-effectiveness are 
grouped under the scheme of primordial, primary, 
secondary and tertiary prevention of CVD and DM 
(table 3). This flow is used to make information available 
in an accessible format for policy-level and clinical deci-
sions. Cost-effectiveness results from observational studies 
have not been included in the final synthesis of cost-ef-
fectiveness data from South Asia due to poor quality of 
evidence. Cost-effectiveness data presented below are 
for India unless otherwise specified (the GDP per capita 
(in US$ 2016) for India, Pakistan and Bhutan are 1861.5, 
1468.2 and 729.5, respectively).28
Primordial prevention
We found that a multicomponent population-level 
policy intervention consisting of increase in tobacco 
tax, clean indoor air law, advertisement ban and infor-
mation/labelling are all highly cost-effective than 
increased tobacco tax alone (<1×GDP per capita per 
DALY averted).29 Addition of ‘nicotine replacement 
therapy’, ‘brief advice’ or ‘physician counselling’ to 
the combination strategy for tobacco control was not 
cost-effective (>3×GDP per capita per DALY averted).29 
Complete smoking ban in public places is also highly 
cost-effective in terms of life years gained and acute 
myocardial infarction averted.30 School-based smoking 
prevention programme as evaluated in a cluster 
randomised trial in India31 was found to be cost-ef-
fective (1–3×GDP per capita per QALY gained). Salt 
reduction by legislation was cost-effective (1–3×GDP 
per capita per DALY averted).29 32 Substitution of trans 
fat with polyunsaturated fatty acids was cost-effective 
compared with null scenario (no intervention) per 
DALY averted.32 Media campaign to reduce saturated 
fat content was also cost-effective per DALY averted.32 
A combined intervention of salt reduction by means of 
legislation together with public education campaign 
is cost-effective too.32 Alcohol taxation combined with 
advertisement ban was the most cost-effective strategy 
for alcohol control.15
Primary prevention
A 2015 modelling study conducted in Bhutan demon-
strated that universal screening for diabetes and hyperten-
sion was highly cost-effective compared with no screening 
(<1×GDP per capita per QALY gained).33 Another 2006 
modelling study from India34 showed that screening undi-
agnosed diabetes and treating those who test positive were 
not cost-effective, with an ICER of US$11 671 per DALY 
averted (ie, >3×GDP per capita for India), suggesting 
that screening for diabetes alone was not cost-effective 
and it should be supplemented with other risk factors, 
for example, hypertension. Other factors that could have 
influenced conflicting results include different health 
system-related cost, different model structure/model 
parameters, disease prevalence and time period.
Screening for gestational DM to prevent DM was also 
cost-effective compared with no screening.35
Among clinical interventions, preventive multi-
drug treatment provided to those at >35% cardio-
vascular risk vs 5% cardiovascular risk over 10 years 
was more cost-effective.29 Combined strategy of home 
health education plus trained general physician for 
Figure 3 Technical characteristics of decision modelling studies.  This figure presents the number of decision modelling 
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<GDP per capita per 
QALY=green;




Tobacco control strategies (Ortegón et al29) Incremental DALYs 
averted per million 
population
  Increased taxation (60%) No intervention Lifetime 0.27 3043 207
  Tax increase+advertisement ban Increased taxation Lifetime 0.1 607.0 423
  Tax increase+clean indoor air law Increased taxation Lifetime 0.09 574 366
  Tax increase+information/labelling Tax increase+clean indoor air law Lifetime 0.11 485 529
  Tax increase+advertisement  
ban+clean indoor air law Tax increase+clean indoor air law Lifetime 0.12 683 410
  Tax increase+advertisement  
ban+information/labelling
Tax increase+advertisement
ban+clean indoor air law Lifetime 0.11 485 529
  Tax increase+clean indoor air 
law+advertisement ban+information and 
labelling
Tax increase+advertisement
ban+clean indoor air law Lifetime 0.20 996.0 468
Tobacco control strategies (Jha et al60)
  33% price increase—low-end effect 
estimate No intervention Lifetime 5
  33% price increase—high-end effect 
estimate No intervention Lifetime 71
  Non-price interventions‡ effectiveness 
2%–10%—low-end estimate No intervention Lifetime 89
  Non-price interventions‡ effectiveness 
2%–10%—high-end estimate No intervention Lifetime 1132
Complete smoking ban in public 
places (Donaldson et al30)
Current legislation for partial smoking 
ban in public places 10 years −36 056 957




School-based smoking prevention programme 
(Brown et al31) No intervention 175 438.5
4.52 (QALY/smoker 
averted) 4501
Promoting healthy diet strategies (Cecchini 
et al32)
  Food labelling No intervention 20 years 2220
  Fiscal measure for 100% population No intervention 50 years Cost-saving
  Food advertising regulation No intervention 50 years 774
  Food labelling No intervention 50 years 1810
Promoting healthy diet strategies (Murray et 
al57)
  Salt reduction through voluntary agreements 
with industry No intervention Lifetime 106
  Population-wide reduction in salt intake 
legislation No intervention Lifetime 54
  Health education through mass media No intervention Lifetime 40
  Salt reduction via 
legislation+health education via mass media No intervention Lifetime 49
Promoting healthy diet strategies (Willett et al5) Lifetime
  Media campaign to reduce saturated fat 
content No intervention Lifetime 5086
  Substitute 2% of energy from trans fat with 
polyunsaturated fatty acid (7% coronary 
artery disease reduction at $0.5 per adult)
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<GDP per capita per 
QALY=green;
1–3×GDP per capita 
per QALY=yellow
  Substitute 2% of energy from trans fat with 
polyunsaturated fatty acid (7% coronary 
artery disease reduction at $0.6 per adult) No intervention Lifetime 2765
  Substitute 2% of energy from trans fat with 
polyunsaturated fatty acid (40% coronary 
artery disease reduction at $0.5 per adult) No intervention Lifetime Cost-saving
  Substitute 2% of energy from trans fat with 
polyunsaturated fatty acid (40% coronary 
artery disease reduction at $0.6 per adult) No intervention Lifetime 376
  Reducing salt content by means of 
legislation+public education No intervention Lifetime 3613
Blood pressure-lowering strategies (Rodgers 
et al59) Lifetime
  Prevention by salt legislation No intervention Lifetime 49
Alcohol control strategies (Chisholm et al15)
  Taxation current+25% (alcohol use) No intervention Lifetime Cost-saving
  Taxation current+50% (alcohol use) No intervention Lifetime Cost-saving
  Breath testing No intervention Lifetime 152
  Highest tax+advertisement ban No intervention Lifetime 5002
Primary prevention
Policy interventions
Universal screening for diabetes and 
hypertension (Dupka et al73)§
DALY averted per 
person
  Current Package of Essential Non-
Communicable (PEN) disease interventions 
programme No screening Lifetime −77.2 0.038 Cost-saving
  Universal screening Current WHO-PEN programme Lifetime −33.1 0.016 Cost-saving
Screening for GDM to prevent DM (Lohse
et al66) No intervention Lifetime 26 2.33 16
Screening to prevent GDM (Marseille et al35) No intervention Lifetime 194 358 120 2317
Expansion of national insurance to cover 




  Insurance coverage for primary prevention 
of CVD Status quo 20 years 1.19 2544.5 528
Clinical interventions
Tobacco control strategies (Jha et al60)
  Nicotine replacement therapy effectiveness 
1%–5%—low-end estimate No intervention Lifetime 142
  Nicotine replacement therapy effectiveness 
1%–5%—high-end estimate No intervention Lifetime 1880
To reduce alcohol use (Chisholm et al15)
  Brief physician advice No intervention Lifetime 175
CVD prevention strategies (Ortegón et al29) Incremental DALYs 
averted per million 
population
Preventive multidrug treatment (>5% risk 
of CVD event) No intervention Lifetime 1.97 4542 4238
Preventive multidrug treatment (>35% risk of 
CVD event)
Preventive multidrug treatment 
(>5% risk of CVD event) Lifetime 0.38 2582 341
Combination of individual-based drug
therapy for hypertension and cholesterol
control
Preventive multidrug treatment 
(>5% risk of CVD event)
Lifetime 1.8 1780 2358









pen: first published as 10.1136/bmjopen-2017-017809 on 3 April 2018. Downloaded from 















<GDP per capita per 
QALY=green;
1–3×GDP per capita 
per QALY=yellow
Combined home health education plus 
trained general practitioner for hypertension 
management (Jafar  et al36)¶ No intervention 2 years 48
Diabetes prevention strategies (Narayan
et al34)
  Smoking cessation (physician counselling 
and nicotine replacement therapy) No intervention Lifetime 1990.6
  Preconception care for women of 
reproductive age No intervention Lifetime Cost-saving
  Lifestyle interventions to prevent type 2 
diabetes No intervention Lifetime 163.6
  Metformin intervention to prevent type 2 
diabetes No intervention Lifetime 4962.9
Lifestyle modification+metformin to prevent 
type 2 diabetes (Ramachandran et al37)
Number needed to 
treat to prevent a 
case of diabetes
  Lifestyle modification Standard healthcare advice 3 years 164 6.4 2302
  Metformin Standard healthcare advice 3 years 159 6.9 2396
  Lifestyle modification+metformin Standard healthcare advice 3 years 209 6.5 2973
Secondary and tertiary prevention
Policy interventions
Policies to expand use of drugs for acute 
myocardial infarction (Megiddo et al38)
Acute myocardial infarction treatment
  Aspirin to baseline No intervention Lifetime 0.6
  Aspirin+injection streptokinase Aspirin to baseline Lifetime 693
Acute myocardial infarction prevention
  Aspirin to baseline No intervention Lifetime 299
  Aspirin+BB Aspirin to baseline Lifetime 1960
  Aspirin+BB+ACEi Aspirin+BB Lifetime 3120
  Polypill to baseline Aspirin+BB+ACEi+statin Lifetime 1904
Expansion of national insurance to cover 




  Insurance coverage for secondary 
prevention of CVD Status quo 20 years 0.36 147.9 2708
  Insurance coverage for tertiary treatment 
of CVD Status quo 20 years 4.68 2076.8 2538
Clinical interventions
CVD treatment strategies (Ortegón et al29) Incremental DALYs 
averted per million 
population
  Treatment of CHF with diuretics No intervention Lifetime 0.03 402 188.9
  Treatment of CHF with diuretics+exercise 
training Treatment of CHF with diuretics Lifetime 0.02 60 776.6
  Treatment of CHF with 
diuretics+exercise training+ACEi Treatment of CHF with diuretics Lifetime 0.04 72 1296.7
  Treatment of CHF with 
diuretics+exercise training+BB Treatment of CHF with diuretics Lifetime 0.08 95 1963
  Treatment of post-acute ischaemic heart 
disease and stroke with aspirin, BB, statin
No intervention Lifetime 0.03 609 114
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QALY=green;
1–3×GDP per capita 
per QALY=yellow
  Treatment of acute myocardial infarction 
(aspirin, BB, ACEi, streptokinase)+post-
acute ischaemic heart disease with aspirin, 
BB, statin No intervention Lifetime 0.36 1047 799
  Treatment of acute myocardial infarction 
(aspirin, BB, ACEi, streptokinase)+post-
acute ischaemic heart disease with aspirin, 
BB, statin, ACEi
Treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease with aspirin, BB, statin Lifetime 0.37 945 914
  Treatment of acute myocardial infarction 
(aspirin, BB, ACEi, streptokinase)+post-
acute ischaemic heart disease and stroke 
with aspirin, BB, statin No intervention Lifetime 0.04 263 354
  Treatment of acute myocardial infarction 
(aspirin, BB, ACEi, streptokinase)+post-
acute ischaemic heart disease and stroke 
with aspirin, BB, statin+CHF (diuretic, 
exercise)
Treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease and stroke with aspirin, 
BB, statin Lifetime 0.26 1879 321
  Individual-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease (aspirin, BB, statin) No intervention Lifetime 2.57 5526 1084
  Individual-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease (aspirin, BB, ACEi, statin)
Individual-based prevention 
(hypertension and cholesterol 
control)+treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease (aspirin, BB, statin) Lifetime 0.04 250 373
  Individual-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease and stroke (aspirin, BB, statin)
Individual-based prevention 
(hypertension and cholesterol 
control)+treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease (aspirin, BB, ACEi, 
statin) Lifetime 0.04 201 464
  Individual-based prevention (hypertension 
and cholesterol control)+treatment of post-
acute ischaemic heart disease and stroke 
(aspirin, BB, statin)+CHF (diuretic, exercise)
Individual-based prevention 
(hypertension and cholesterol 
control)+treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease and stroke (aspirin, BB, 
statin) Lifetime −0.23 119 Cost-saving
  Individual-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease and stroke (aspirin, BB, statin)+CHF 
(diuretic, exercise)
Individual-based prevention 
(hypertension and cholesterol 
control)+treatment of post-acute 
ischaemic heart disease and stroke 
(aspirin, BB, statin)+CHF (diuretic, 
exercise) Lifetime 0.26 437 1387
  Combination drug treatment (>25% risk 
of CVD event)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+treatment of post-acute 
ischaemic heart disease (aspirin, BB, statin) No intervention Lifetime 1.16 4852 557
  Combination drug treatment (>25% risk 
of CVD event)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+treatment of post-acute 
ischaemic heart disease (aspirin, BB, ACEi, 
statin)
Combination drug treatment 
(>25% risk of CVD event)+treatment of 
acute myocardial infarction (aspirin, 
BB, ACEi, streptokinase)+treatment of 
post-acute ischaemic heart disease 
(aspirin, BB, statin) Lifetime 0.04 237 394
  Combination drug treatment (>25% risk 
of CVD event)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+treatment of post-acute 
ischaemic heart disease and stroke (aspirin, 
BB, statin)
Combination drug treatment 
(>25% risk of CVD event)+treatment of 
acute myocardial infarction (aspirin, 
BB, ACEi,  streptokinase)+treatment of 
post-acute ischaemic   heart   disease 
(aspirin, BB, ACEi, statin)
Lifetime 0.04 178 524
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  Combination drug treatment (>25% risk 
of CVD event)+treatment of post-acute 
ischaemic heart disease and stroke (aspirin, 
BB, statin)+CHF (diuretics, exercise)
Combination drug treatment 
(>25% risk of CVD event)+treatment of 
acute myocardial infarction (aspirin, 
BB, ACEi, streptokinase)+treatment of 
post-acute ischaemic   heart   disease 
and stroke (aspirin, BB, statin) Lifetime −0.23 32 Cost-saving
  Preventive multidrug treatment for >25% risk 
of CVD event+multidrug treatment of 
acute myocardial infarction or post-
acute ischaemic heart disease and 
stroke+diuretics and exercise for CHF
Combination drug treatment 
(>25% risk of CVD event)+treatment of 
post-acute ischaemic   heart   disease 
and stroke (aspirin, BB, statin)+CHF 
(diuretics, exercise) Lifetime 0.26 558 1086
  Combination drug treatment (>35% risk 
of CVD event)+treatment of post-acute 
ischaemic heart disease and stroke (aspirin, 
BB, statin)+CHF (diuretics, exercise)
Combination drug treatment 
(>35% risk of CVD event)+treatment of 
post-acute ischaemic heart disease 
and stroke (aspirin, BB, statin)+CHF 
(diuretics, exercise) Lifetime −0.23 31 Cost-saving
  Preventive multidrug treatment for >35% risk 
of CVD event+multidrug treatment of 
acute myocardial infarction or post-
acute ischaemic heart disease and 
stroke+diuretics and exercise for CHF
Combination drug treatment 
(>35% risk of CVD event)+treatment of 
post-acute ischaemic heart disease 
and stroke (aspirin, BB, statin)+CHF 
(diuretics, exercise) Lifetime 0.26 630 963
CVD treatment strategies (Murray et al57)
  Treatment of SBP above 160 mm Hg with BB 
and diuretic No intervention Lifetime 103.2
  Treatment of SBP above 140 mm Hg with BB 
and diuretic No intervention Lifetime 257.9
  Treatment with statins for total cholesterol 
concentrations above education 6.2 mmol/L No intervention Lifetime 134.7
  Treatment with statins for total cholesterol 
concentrations above education 5.7 mmol/L No intervention Lifetime 203.5
  Treatment of SBP above 140 mm Hg with 
BB and diuretics and with statins for total 
cholesterol concentrations above 6.2 mmol/L No intervention Lifetime 240.7
  Multiple drug therapy in >35% CV risk over 
10 years No intervention Lifetime Cost-saving
  Multiple drug therapy in >25% CV risk over 
10 years No intervention Lifetime 94.6
  Multiple drug therapy in >15% CV risk over 
10 years No intervention Lifetime 137.5
  Multiple drug therapy in >5% CV risk over 
10 years No intervention Lifetime 220.7
CVD treatment and secondary prevention 
(Gaziano et al43)
  Medical therapy for acute myocardial 
infarction with aspirin No intervention Lifetime 25.8
  Medical therapy for acute myocardial 
infarction with aspirin+BB No intervention Lifetime 31.5
  Medical therapy for acute myocardial 
infarction with aspirin+BB+streptokinase No intervention Lifetime 1828.8
  Medical therapy (aspirin+BB) for ischaemic 
heart disease, having hospital access No intervention Lifetime Cost-saving
  Medical therapy (aspirin+BB+ACEi) for 
ischaemic heart disease, having hospital 
access No intervention Lifetime 2049.5
  Medical therapy (aspirin+BB+ACEi+statin) 
for ischaemic heart disease, having hospital 
access No intervention Lifetime 5214.2
  Medical therapy (aspirin+BB) for ischaemic 
heart disease, limited hospital access
No intervention Lifetime 1106.4
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  Medical therapy (aspirin+BB+ACEi) for 
ischaemic heart disease, limited hospital 
access No intervention Lifetime 2373.4
  ACEi for CHF, hospital access Baseline of diuretics Lifetime Cost-saving
  ACEi, BB (metoprolol) for CHF, hospital 
access Baseline of diuretics Lifetime 627.7
  ACEi for CHF, limited hospital access Baseline of diuretics Lifetime 71.6
  ACEi, BB (metoprolol) for CHF, limited 
hospital access Baseline of diuretics Lifetime 782.5
Blood pressure-lowering strategies (Rodgers 
et al59)
  Multidrug regimen (aspirin, a BB, a thiazide 
diuretic, an ACEi and a statin) in 35% CV 
risk over 10 years No intervention Lifetime 1827
  Multidrug regimen (aspirin, a BB, a thiazide 
diuretic, an ACEi and a statin) in 25% CV 
risk over 10 years No intervention Lifetime 3408.6
  Multidrug regimen (aspirin, a BB, a thiazide 
diuretic, an ACEi and a statin) in 15% CV 
risk over 10 years No intervention Lifetime 5268.2
Treat-to-target, benefit-based tailored 
treatment strategy vs hybrid strategy for 
lowering CVD risk (Basu et al78)
  People treated identically by all three 
strategies No intervention 10 years 383.7
  People treated most intensively by treat-to-
target No intervention 10 years 432.1
  People treated most intensively by benefit-
based tailored treatment No intervention 10 years 206.1
  People treated most intensively by hybrid No intervention 10 years 384.4
Prehospital ECG for accurate referral and 
timely access to reperfusion (Schulman-
Marcus et al40)




Diabetes treatment strategies (Narayan
et al34) Lifetime
  Glycaemic control in people with 
HbA1c >9% (insulin, oral glucose-lowering 
agents, diet and exercise) No intervention Lifetime Cost-saving
  Blood pressure control in people with 
>160/95 mm Hg No intervention Lifetime Cost-saving
  Foot care in people with a high risk of ulcers No intervention Lifetime Cost-saving
  Influenza vaccination among elderly No intervention Lifetime 490.8
  Annual eye examination No intervention Lifetime 954.4
  ACEi use for people with diabetes No intervention Lifetime 1390.7
  Intensive glucose control for people with 
HbA1c >8% (insulin, oral glucose-lowering 
agents or both) No intervention Lifetime 5453.7
Treatment of diabetes and its 
complications (Ortegón et al29)
Incremental DALYs 
averted per million 
population
  Standard glycaemic control No intervention Lifetime 0.82 1717 1115
  Retinopathy screening and photocoagulation 
therapy No intervention Lifetime 0.32 1891 396.4
  Standard glycaemic control+retinopathy
  screening+neuropathy screening
Intensive glycaemic 
control+neuropathy screening
Lifetime −0.65 213 Cost-saving
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  BIAsp 30 BHI 30 or IGlar 30 years 868.496 2.52 412.9
  BIAsp 30  NPH insulin 30 years −2524.192 2.82 Cost-saving
  BIAsp 30 IGlar 30 years 527.232 2.74 228.8
  BIAsp 30 BHI 30 or IGlar 1 year 123.264 0.21 684.2
  BIAsp 30 IGlar 1 year 93.984 0.23 487.2




  Basal insulin treatment with insulin detemir Oral glucose-lowering drugs 30 years 3510.36 4.97 834.1
  Basal insulin treatment with insulin detemir Oral glucose-lowering drugs 1 year 338.796 0.322 1243.4





  Screening once in a lifetime No screening 25 years 6.5 0.0049 2214.1
  Screening twice in a lifetime No screening 25 years 5.3 0.0039 2252.7
  Screening every 5 years No screening 25 years 19.6 0.0097 3400.1
  Screening every 3 years No screening 25 years 17.4 0.0084 3411.8
  Screening every 2 years No screening 25 years 18.4 0.0075 4084.5
Societal perspective
  Screening once in a lifetime No screening 25 years 13.2 0.0049 4515.6
  Screening twice in a lifetime No screening 25 years 9.7 0.0039 4151.6
  Screening every 5 years No screening 25 years 30.3 0.0097 5257
Combination of primordial, primary, 
secondary and tertiary prevention
Interventions to reduce hazardous alcohol use 
(Chisholm et al15)
  Highest tax+advertisement ban+brief advice No intervention Lifetime 2562.7
Blood pressure-lowering strategies (Rodgers 
et al59)
  Prevention by salt legislation+health 
education No intervention Lifetime 87.2
  Treatment with aspirin, BB, and a 
statin+salt legislation+health education in 
35% CV risk over 10 years No intervention Lifetime 362.6
  Treatment with aspirin, BB, and a 
statin+salt legislation+health education in 
25% CV risk over 10 years No intervention Lifetime 1576
  Treatment with aspirin, BB, and a 
statin+salt legislation+health education in 
15% CV risk over 10 year No intervention Lifetime 3054
Intervention for CVD prevention and 
treatment (Murray et al57)
  Combination of legislation for salt reduction, 
health education and treatment of 
individuals with combined CV risk of 35% 
with statin, diuretic, BB and aspirin No intervention Lifetime 63
  Combination of legislation for salt reduction, 
health education and treatment of 
individuals with combined CV risk of 25% 
with statin, diuretic, BB and aspirin
No intervention Lifetime 89
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per DALY averted than individual strategies or no 
intervention in Pakistan.36
Lifestyle modification (weight reduction, increased 
activity and healthy diet) was most cost-effective for 














<GDP per capita per 
QALY=green;
1–3×GDP per capita 
per QALY=yellow
  Combination of legislation for salt reduction, 
health education and treatment of 
individuals with combined CV risk of 15% 
with statin, diuretic, BB and aspirin No intervention Lifetime 132
  Combination of legislation for salt 
reduction, health education and treatment 
of individuals with combined CV risk of 5% 
with statin, diuretic, BB and aspirin No intervention Lifetime 212
CVD prevention and treatment 
strategies (Ortegón et al29)
Incremental DALYs 
averted per million 
population
  Population-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease (aspirin, BB, statin) No intervention Lifetime 0.55 2376 538
  Population-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease (aspirin, BB, ACEi, statin)
Population-based prevention 
(hypertension and cholesterol 
control)+treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease (aspirin, BB, statin) Lifetime 0.04 285 326
  Population-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic heart 
disease and stroke (aspirin, BB, statin)
Population-based prevention 
(hypertension and cholesterol 
control)+treatment of acute myocardial 
infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute ischaemic 
heart disease (aspirin, BB, ACEi, 
statin) Lifetime 0.04 246 380
  Population-based prevention (hypertension 
and cholesterol control)+treatment of acute 
myocardial infarction (aspirin, BB, ACEi, 
streptokinase)+post-acute Ischaemic heart 
disease and stroke (aspirin, BB, statin)+CHF 
(diuretic, exercise)
Population-based prevention 
(hypertension and cholesterol 
control)+treatment of post-acute 
ischaemic heart disease and stroke 
(aspirin, BB, statin)+CHF (diuretic, 
exercise) Lifetime 0.26 646 937
Expansion of national insurance to cover 




  Insurance coverage for 
primary+secondary prevention of CVD Primary prevention only 20 years 0.35 145.0 2739
  Insurance coverage for 
primary+tertiary prevention of CVD Primary prevention only 20 years 4.67 2084.6 2525
GDP per capita (US$, 2016) for India, Pakistan and Bhutan are 1861.5, 1468.2 and 729.5, respectively.
*Values refer to original study period.
†Conversion to current year, based on midyear consumer price index inflation rates.
‡Non-price interventions to reduce tobacco use:
–protection from exposure to tobacco smoke 
–regulation of the contents of tobacco products 
–regulation of tobacco product disclosures 
–packaging and labelling of tobacco products 
–education, communication, training and public awareness 
–tobacco advertising, promotion and sponsorship 
–demand reduction measures concerning tobacco dependence and cessation. 
§Conducted in Bhutan.
¶Conducted in Pakistan.
ACEi, ACE inhibitors; BB, beta-blockers (blood pressure-lowering agents; BHI, biphasic human insulin; BIAsp 30, biphasic insulin aspart 30; CHF, congestive 
heart failure; CV, cardiovascular; CVD, cardiovascular diseases; DALY, disability-adjusted life years; DM, diabetes mellitus; GDM, gestation diabetes mellitus; GDP, 
gross domestic product; HbA1c, glycated haemoglobin; ICER, incremental cost-effectiveness ratio; IGlar, insulin glargine; QALY, quality-adjusted life years; NPH, 
neutral protamine Hagedorn; SBP, systolic blood pressure. 
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combination of lifestyle modification plus metformin 
(1–3×GDP per capita).37
secondary and tertiary prevention
Policies to expand access of drugs for acute myocardial 
infarction prevention and treatment were cost-effective 
per DALY averted.38 Also, expansion of national insur-
ance to cover secondary or tertiary prevention of CVD 
was most cost-effective per QALY gained compared with 
status quo.39 Clinical interventions for secondary preven-
tion of CVD are mostly cost-effective per DALY averted.29 
ECG-based doctor referral to cardiac care unit versus no 
‘ECG use’ was cost-effective per QALY gained.40
Many strategies for DM treatment and secondary 
prevention of macrovascular and microvascular complica-
tions were found to be highly cost-effective or cost-effec-
tive. Examples of highly cost-effective interventions are 
glycaemic control in people with glycated haemoglobin 
(A1c) >9% with insulin, oral glucose-lowering drugs, diet 
and exercise, BP control in people with >165/95 mm 
Hg, and foot care in people with high risk of ulcers 
(<1×GDP per capita per DALY averted).34 Basal insulin 
treatment versus oral glucose-lowering drugs was highly 
cost-effective (<1×GDP per capita per QALY gained).41 
Diabetic retinopathy screening every 2–5 years versus 
no screening was cost-effective (1–3×GDP per capita per 
QALY gained).27
Combination of primordial, primary, secondary and tertiary 
prevention
Multicomponent strategies of salt reduction through 
legislation (increase tax), health education, plus treat-
ment of individuals at 35% cardiovascular risk with statin, 
diuretic, beta-blockers and aspirin were highly cost-effec-
tive, followed by similar strategy in those at 25% or 15% 
cardiovascular risk over 10 years.29 Policy measures such as 
expansion of insurance coverage for primary, secondary 
and tertiary prevention of CVD were also cost-effective 
(1–3×GDP per capita per DALY averted).39
Interventions that resulted in ICER>3×GDP per capita 
or were dominated by other highly cost-effective strategies 
are presented in online supplementary table 1. Signifi-
cant heterogeneity in analytical framework and outcome 
measures used in these studies restricted meta-analysis 
and direct ranking of the interventions by their degree of 
cost-effectiveness.
dIsCussIOn
This review finds that, with some exceptions, most 
interventions to control CVD and DM were cost-effec-
tive (<1–3×GDP per capita per QALY gained or DALY 
averted), although the strength of evidence (and risk of 
bias) varied across economic evaluations based on obser-
vational studies, RCTs and decision models. Most inter-
ventions were cost-effective because of the large benefits 
in DALY averted or QALY gained at a marginal increase 
in cost per capita ($). These results should motivate 
decision makers to invest in primordial prevention strat-
egies (increased tobacco tax, salt reduction by legisla-
tion, food labelling and food advertising regulation), 
and primary and secondary prevention interventions: 
multidrug therapy for CVD prevention and treatment in 
high-risk groups, lifestyle modification and metformin for 
diabetes prevention, and screening for diabetes compli-
cations every 2–5 years. Although detecting and treating 
diabetes earlier can prevent future complications and 
their associated medical costs, such savings were shown 
to be relatively small.34 An alternative to broad screening 
is to focus on targeted screening, that is, screening only 
persons with additional risk factors, such as hyperten-
sion and obesity. Such targeted screening was shown to be 
highly cost-effective or cost-saving when compared with 
no screening.33
Choice of comparator is an important decision when 
evaluating ICER of new interventions. In general, model-
ling studies that used the WHO-CHOICE method have 
reported average cost-effectiveness ratio against the null 
scenario (no intervention). In reality, however, this does 
not seem plausible because null scenario will not always 
reflect zero costs and zero effects. Also, these studies first 
identified the most cost-effective intervention among 
a group of strategies (eg, tobacco control, CVD preven-
tion and treatment, or diabetes prevention and treat-
ment) versus null scenario, then compared it with the 
next most cost-effective intervention.29 In many of such 
analysis, because the description of comparator was not 
clearly specified, the reported ICERs look ambiguous and 
changing the ‘comparator’ might produce a different 
ICER.
In our formal appraisal of the methodological quality 
of studies, we observed limitations in documentation of 
main study details, for example, chosen study perspec-
tive, sources of cost data and analytical time horizon. In 
addition, significant number of studies failed to provide 
details on units of resource use, costing year, currencies 
and other economic aspects. Since the discount rate used 
has an impact on cost-effectiveness estimates, the zero-dis-
count rate applied in some studies is deeply concerning. 
In reality, however, every economic evaluation will contain 
some degree of uncertainty or imprecision. While one-way 
sensitivity analysis is helpful in understanding the impact 
of assumptions about one input parameter, multi-way 
sensitivity analysis offers a robust method to explore the 
uncertainty concerning more than one input parameters, 
but few studies reported results using this technique.
In terms of comparing results of this review with 
other contemporary reviews, we found cost-effectiveness 
evidence on a large number of preventive strategies, 
which is inconsistent with a previous review that exam-
ined the economic evaluation from Health Economic 
Evaluation Database42 and concluded that only 10% of all 
evaluations assessed preventive care. The greater number 
of preventive strategies found in our review could be due 
to the development of the WHO-CHOICE programme26 
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Although cost-effectiveness evidence is available for 301 
interventions to control CVD or DM, most of this evidence 
is based on decision models, which used data (annual 
risk of disease progression and intervention benefits) 
from Western countries. Most decision model studies 
have derived treatment effects from either meta-analysis 
of RCTs if available for an intervention or single RCT 
if meta-analysis is not available. However, the limited 
representation of South Asian populations in those RCTs 
remains an important concern. Therefore, our review 
highlights an alarming paucity of local research data to 
conduct high-quality economic evaluations and reflect 
the concerns of others in the field that large research 
gaps do remain in the area of health economic analysis 
in South Asian countries.44 Also, data from countries 
other than India are sparse. This is likely a reflection of 
research capacity in these countries, which needs to be 
addressed as a priority. Although the countries in South 
Asia are frequently grouped together, various countries 
in this region have substantially different health systems, 
health literacy, health indices, and hence healthcare 
needs. Understanding the differences be the countries 
is critical for policy makers, and therefore additional 
economic evaluations are urgently needed from other 
South Asian countries.
strengths and limitations
This review has several strengths. This is the first study, 
to our knowledge, to include all types of interventions 
(policy, clinical and behavioural) that affect CVD or DM 
in South Asia. We considered all possible interventions 
(primordial, primary, secondary and tertiary prevention) 
to control CVD and DM together in this systematic review, 
primarily because policy makers have to choose between 
different options (competing priorities) for appropriate 
resource allocation, and as such a narrow economic 
research question is really not helpful for the systematic 
review, which intends to inform the process. We have used 
explicitly stated methods (protocol paper published)19 
and standard checklists to assess methodological quality 
of studies. Recently, new methods have been proposed 
by researchers that can be applied to review decision 
model studies.45 However, use of new criteria would not 
change the findings of this review because these points 
have been covered broadly by the three popular check-
lists that we used in this review. Also, new methods have 
been proposed to estimate country-specific threshold 
for cost-effectiveness based on opportunity cost (health 
forgone) with investment in new intervention.46 But we 
preferred to present the findings based on WHO guide-
lines25 and for a lower threshold, that is, 1×GDP per capita. 
Moreover, the incremental cost and incremental benefits 
have been shown for all interventions (where available) 
so the decision makers or clinicians can make consider-
ations based on their own willingness to pay threshold or 
budgetary constraints.
This review is not without limitations. First, the search 
was restricted to English-language publications performed 
as of August 2016. But this would not be a major problem 
because all the South Asian countries mostly publish 
research in English. Second, we excluded unpublished 
and ‘grey’ literature as we wanted to include studies that 
have undergone peer review process. We believe though 
that no major studies that can change the results of this 
review have been missed.
The review findings should be interpreted with caution 
because most of the cost-effectiveness studies were based 
on decision models. Although good-quality decision 
modelling study can provide information at a lower 
cost than RCT-based economic evaluations, models are 
based on assumptions and represent a simplification 
of—and therefore might depart from—reality. Further-
more, interventions that were highlighted as cost-effec-
tive (yellow) or highly cost-effective or dominant (green) 
analysed using the WHO-CHOICE framework could be 
reassessed by local agencies, particularly with regard to 
budget impact and also their cost-effectiveness, taking 
into account local costs and willingness to pay threshold 
value, similar to the work carried out by the Health Inter-
vention and Technology Assessment Program in Thailand 
over the past decade.47
Future research directions
We have identified key research gaps in this review. Inter-
ventions involving multisectoral approach and policies for 
change in drug prices or devices (stents prices) have not 
been evaluated for their cost-effectiveness. The cost-effec-
tiveness of these interventions should be assessed.
A few recommendations to advance the research on 
economic evaluations in the region are as follows. First, 
future studies need to take a broader societal perspec-
tive for analysis and present cost data in disaggregated 
form (resource consumption and unit costs, separately). 
Second, more research is needed to support the causes 
of variation among costs, effects and cost-effectiveness 
data on the universal screening of diabetes and/or hyper-
tension. Third, research should focus on assessing the 
generalisability of cost-effectiveness analysis results within 
and between countries. Lastly, future cost-effectiveness 
analysis studies should adhere to international guidelines 
proposed by the WHO,25 International Society for Phar-
macoeconomics and Outcomes Research,48–51 and the 
recommendations of the Second Panel on Cost-Effective-
ness in Health and Medicine52 as a benchmark for design, 
conduct and reporting.
COnClusIOn
The existing economic evidence base from South Asia 
should motivate policy makers to mobilise resource allo-
cation towards the most cost-effective interventions iden-
tified in this review to curb the epidemic of CVD and DM 
in the region. Also, there is an urgent need to invest in 
health technology assessment and policy evaluations in 
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